Rossella De Leo

Rossella De Leo

Auto-generated profile, based on publicly available information

Rossella De Leo

Department of Woman and Child Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Roma, Italia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
MPMarco Petrillo
Marco Petrillo
CMClaudia Marchetti
Claudia Marchetti
RLRossella De Leo
Rossella De Leo
AMAngela Musella
Angela Musella
ETTORE CAPOLUONGOETTORE CAPOLUONGO
ETTORE CAPOLUONGO
AFAnna Fagotti
Anna Fagotti

1 November 2014 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
FSfrancesco de seta
francesco de seta
Fabio ParazziniFabio Parazzini
Fabio Parazzini
RLR. De Leo
R. De Leo
RBR. Banco
R. Banco
GMG.P. Maso
G.P. Maso
Stefano RestainoStefano Restaino
Stefano Restaino

20 August 2018 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
CMClaudia Marchetti
Claudia Marchetti
RLRossella De Leo
Rossella De Leo
AMAngela Musella
Angela Musella
MDMarco D’indinosante
Marco D’indinosante
ETTORE CAPOLUONGOETTORE CAPOLUONGO
ETTORE CAPOLUONGO
AFAnna Fagotti
Anna Fagotti

1 January 2015 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
CAChiara Agostinis
Chiara Agostinis
SZS Zorzet
S Zorzet
RLR De Leo
R De Leo
GZGiorgio Zauli
Giorgio Zauli
FSfrancesco de seta
francesco de seta
Roberta BullaRoberta Bulla
Roberta Bulla
To evaluate the efficacy of an association of N‐acetyl cystein, alpha‐lipoic acid, and bromelain (NAC/LA/Br) in the treatment of endometriosis we set up a new in vivo murine model. We explored the anti‐inflammatory and proapoptotic effect of this combination on human endometriotic endothelial cells (EECs) and on endothelial cells isolated from normal uterus (UtMECs). We implanted fragments of human endometriotic cysts intraperitoneally into SCID mice to evaluate the efficacy of NAC/LA/Br treatment. UtMECs and EECs, untreated or treated with NAC/LA/Br, were activated with the proinflammatory stimulus TNF‐α and their response in terms of VCAM1 expression was evaluated. The proapoptotic effect of higher doses of NAC/LA/Br on UtMECs and EECs was measured with a fluorogenic substrate for activated caspases 3 and 7. The preincubation of EECs with NAC/LA/Br prior to cell stimulation with TNF‐α prevents the upregulation of the expression of the inflammatory “marker” VCAM1. Furthermore NAC/LA/Br were able to induce EEC, but not UtMEC, apoptosis. Finally, the novel mouse model allowed us to demonstrate that mice treated with NAC/LA/Br presented a lower number of cysts, smaller in size, compared to untreated mice. Our findings suggest that these dietary supplements may have potential therapeutic uses in the treatment of chronic inflammatory diseases like endometriosis.

1 July 2017 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
FFFrancesco Fanfani
Francesco Fanfani
Stefano RestainoStefano Restaino
Stefano Restaino
SCStefania Cicogna
Stefania Cicogna
MPMarco Petrillo
Marco Petrillo
MMMarcella Montico
Marcella Montico
Giuseppe RicciGiuseppe Ricci
Giuseppe Ricci

4 July 2014 in Gynecological Endocrinology
Verified
Journal Article
Closed access
FSfrancesco de seta
francesco de seta
Stefano RestainoStefano Restaino
Stefano Restaino
RBRubina Banco
Rubina Banco
ECEster Conversano
Ester Conversano
RLRossella De Leo
Rossella De Leo
SLStefano Lello
Stefano Lello
Estroprogestins with "natural oestrogen" has represented a new option in terms of combined hormonal contraception. So, the aim of this study is to investigate how estroprogestins with natural estrogen may modify the vaginal niche. In literature, very few studies focused on the interaction between hormonal contraception and vaginal milieu. This is a prospective comparative study. We enrolled 60 women from January 2013 to September 2013, 30 of them were administered estradiol valerate dienogest (E2V+DNG - Klaira®) in a quadriphasic regimen, while the other 30 women were administered 17-β estradiol with nomestrol acetate (EV+NOMAC - Zoely®) in a monophasic regimen. After a baseline study of vaginal milieu at recruitment of patients (Gram stain with Nugent score, vaginal pH, vaginal wet mount for the quantification of leukocytes, Lactobacilli and/or presence of Candida), we performed the same follow-up after six months of estroprogestin therapy. Our results showed that the women treated with E2V+DNG had a trend of an improvement of vaginal health in terms of increase of lactobacillar flora and reduction of vaginal pH in place of women treated with EV+NOMAC that showed a reduction of cervical mucus. Finally, our data about the effects on vaginal flora exerted by two estroprogestin pills (EPs) containing a natural estrogen suggest slight, but interesting differences in terms of vaginal ecology. These differences could be related to the type of estrogen, type of progestin, regimen of administration and, after all, to the net balance between estrogenic and progestin component of the EPs